ORIGINAL CONTRIBUTION

Expression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosis

Guoli Chen · Xiaoyang Zhou · Stela Florea · Jiang Qian · Wenfeng Cai ·
Zhiguo Zhang · Guo-Chang Fan · John Lorenz · Roger J. Hajjar ·
Evangelia G. Kranias

Abstract Cardiac apoptosis has been considered an important contributing factor to heart failure. Several subcellular mechanisms, including increased protein phosphatase 1 activity, have been suggested to induce apoptosis. Protein phosphatase 1 is regulated by an endogenous inhibitor-1 (I-1) that is activated upon phosphorylation at threonine 35 via protein kinase A. Here, we tested whether cardiac-specific overexpression of a constitutively active (T35D, AA 1-65) inhibitor-1 (I-1c), could also affect cardiac apoptosis and heart failure progression induced by prolonged β-adrenergic stimulation. We found that either acute or chronic expression of I-1c reduced isoproterenol (ISO)-induced apoptosis assessed by nuclear condensation, TUNEL staining and DNA fragmentation. The beneficial effects of I-1c were associated with increased expression of the anti-apoptotic protein Bcl-2, decreased expression of the pro-apoptotic protein Bax and reduced levels of active caspases as well as increased activation of ERK. These findings suggest that mitochondrial signaling and ERK activation may be involved in the I-1c cardioprotective effects against apoptosis induced by prolonged β-adrenergic stimulation.

Keywords Protein phosphatase 1 inhibitor-1 ·
Cardiomyocytes · Apoptosis · ERK · Bad

G. Chen, X. Zhou contributed to the work equally.

G. Chen · X. Zhou · S. Florea · J. Qian · W. Cai · Z. Zhang ·
G.-C. Fan · E. G. Kranias (✉)
Department of Pharmacology and Cell Biophysics,
University of Cincinnati College of Medicine,
231 Albert Sabin Way, Cincinnati, OH 45267-0575, USA
e-mail: Litsa.Kranias@uc.edu

E. G. Kranias
Foundation for Biomedical Research of the Academy of Athens,
11527 Athens, Greece

X. Zhou
Department of Cardiology, Renming Hospital of Wuhan
University, Wuhan 430060, China

J. Lorenz
Department of Molecular and Cellular Physiology,
University of Cincinnati College of Medicine,
231 Albert Sabin Way, Cincinnati, OH 45267-0575, USA

R. J. Hajjar
Cardiovascular Research Center, Mount Sinai School
of Medicine, New York, NY 10029, USA

Introduction

In the last decade, apoptosis has been recognized as an important factor contributing to the onset and progression of various cardiac diseases such as myocarditis, acute myocardial infarction and cardiomyopathy [6, 22]. Although the exact mechanism of apoptosis within the heart is not clearly understood, several studies indicate that apoptosis mediates cardiomyocyte cell death after myocardial infarction and it is a major determinant of the infarct size upon coronary occlusion, provided that sufficient cellular ATP is present to sustain the apoptotic cascades [22]. Particularly, apoptosis plays a considerable role in the development of heart failure, especially in the transition from the compensatory to the failing phase [2, 25]. Furthermore, several anti-apoptotic strategies have shown promising results in heart failure studies induced by different stressors [20].

Previous studies revealed that an active form of inhibitor-1 (I-1c), a specific and potent inhibitor of PP1, enhanced basal cardiac function by affecting the

phosphorylation levels of phospholamban (PLN), and thus the calcium (Ca^{2+}) dynamics in the heart [7, 26]. More importantly, expression of I-1c in mice displayed a dramatic protective effect against the development of heart failure induced by chronic pressure overload [7, 26]. In addition, adenoviral-mediated expression of I-1c in the setting of pre-existing heart failure restored contractile function and halted the progression of heart failure and fibrosis [7, 26].

Given the remarkable involvement of protein phosphatase 1 (PP1) in the induction of apoptosis [16, 21], it is interesting to speculate that the inhibitor-1 may also protect cardiac cells from death, especially due to apoptosis induced by pathological stress. Indeed, a recently published study from our laboratory demonstrated that inducible expression of the I-1c in mice, improved the heart mechanical recovery as well as cell survival following an ischemic insult through inhibition of apoptosis [24]. One of the underlying mechanisms may involve cardioprotection by the elevated peroxiredoxin II in these hearts [38].

As one of the well-recognized etiologies of heart failure, prolonged β-adrenergic stimulation results in cardiomyocyte apoptosis or death [10, 29]. Moreover, elevated PP1 activity and decreased levels of inhibitor-1 were observed following excessive adrenergic drive in failing hearts [4, 11]. In this study, we found that expression of I-1c decreased chronic ISO-induced cellular apoptosis in acutely infected adult rat cardiomyocytes as well as in transgenic hearts. This protective effect may be associated with altered expression/activity of caspase 3, caspase 8, Bcl-2 and ERK, all being considered active players in the apoptotic cascades.

Materials and methods

Myocyte isolation and cell culture

Left ventricular myocytes were isolated from adult male Sprague–Dawley rats ($\sim$250 g; Harlan Laboratory, Indianapolis, IN), as previously described [8, 13]. The animals were handled according to a protocol approved by the Institutional Animal Care and Use Committee at the University of Cincinnati. Following cell isolation, cardiomyocytes were plated on laminin-coated culture dishes for 1–2 h and allowed to recover at 37°C, in a humidified 5% CO_2 incubator. Plated myocytes were then infected with adenovirus expressing the truncated, active form of I-1 (I-1c) at a multiplicity of infection of 500 for 2 h. Following infection, cells were maintained in culture for 24 h before the addition of ISO (10 μmol/L, Sigma, St. Louis, MO). All dishes were supplemented with ascorbic acid

(0.1 mmol/L, Sigma, St. Louis, MO) to prevent oxidation of ISO.

Animal preparation and osmotic mini-pump infusion

Generation of mice with cardiac-specific expression of truncated T35D-inhibitor-1 has been described previously [7, 26]. Adult wild-type (WT) and transgenic mice (TG), inbred on a FVB/N background, were studied at 8–10 weeks of age. All procedures were in accordance with the Institutional Guidelines for Animal Research. Osmotic minipumps (model 2002; Alzet) containing saline solution or ISO (50 μg/g per day), were implanted into 10-week-old male mice over a period of 14 days, as described previously [14]. Following 14 days of chronic ISO treatment, the pumps were excised and the hearts were immediately collected for subsequent experiments. In some experiments, the pumps were excised after 12 days of ISO treatment and cardiac contractile parameters were assessed by catheterization after 2 days [23]. The heart rate, and the first derivative of left ventricular (LV) pressure development ($+dP/dt$) and decline ($-dP/dt$) were monitored.

Heart homogenates and immunoblotting

Hearts were snap frozen in liquid nitrogen and homogenized in Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA) supplemented with phenylmethylsulphonyl fluoride 1 mM (PMSF) and complete protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN). Equal amounts of protein samples from individual heart homogenates were analyzed by SDS-PAGE, as previously described [28]. Immunoblotting analysis was performed using primary antibodies at 1:1,000 dilution, corresponding to the protein under analysis: Bcl-2 and Bax (from Invitrogen, Carlsbad, CA), caspase-3 (Asp175), caspase-8 and phosphorylated/total p38, ERK, JNK, Akt, Bad (Cell Signaling, Danvers, MA) and α-actin (Sigma, St. Louis, MO). The secondary antibody conjugated with horseradish peroxidase was used at a 1:5,000 dilution. The protein bands were visualized using the SuperSignal West Pico chemiluminescence substrate kit (Pierce, Rockford, IL) or the ECL-PLUS Western Blotting Detection kit (Amersham Pharmacia Biotech, Piscataway, NJ). Signals were quantified using ImageQuant 5.2 analysis software (GE Healthcare, Little Chalfont, UK). The densitometric values corresponding to TG samples were normalized to control WT samples. The data were expressed as fold change relative to control values. Actin was used as an internal standard. The findings were similar to those obtained with calsequestrin as an internal standard.

Detection of apoptosis using terminal dUTP nick end-labeling (TUNEL) assay

Mouse hearts were collected and the atrial tissue was removed. The ventricles were fixed in 10% buffered formalin and then embedded in paraffin according to standard procedures. The TUNEL assay was performed on 3 sections each 3 μm thick, using the ApopTag Plus Peroxidase In situ Apoptosis Detection Kit (Chemicon, Burlington, MA), according to the manufacturer's instructions. The kit detects the DNA strand breaks generated upon DNA fragmentation by enzymatically labeling the 3′-OH ends in the apoptotic bodies with chemically labeled nucleotides. TUNEL-positive nuclei were counted on each mid-ventricular section from ten randomly chosen fields per section. The TUNEL-positive nuclei were expressed as a percentage of the total counted nuclei.

Detection of apoptosis by measuring nuclear DNA fragmentation and DNA condensation

Following ISO treatment, mouse hearts were collected and homogenized in cell lysis buffer (RIPA) containing 1 μmol/L dithiothreitol (DTT) and 50 μmol/L PMSF. The heart homogenates were centrifuged at 13,000g for 10 min and apoptosis was assessed in the supernatants using the Cell Death Detection ELISA^{PLUS} assay kit (Roche, Indianapolis, IN). The kit employs a photometric enzyme immunoassay for quantitative in vitro determination of the cytoplasmic histone-associated DNA fragments. The measurements corresponding to the individual samples were normalized to a positive control provided in the kit, consisting of a DNA–histone complex and expressed as percentages in relation to the positive control. Alternatively, we used Hoechst 33342 a fluorescent dye that stains the condensed chromatin in apoptotic cells more brightly than the chromatin in normal cells. Data were expressed as the number of pyknotic nuclei counted in cells infected with a virus carrying I-1c in the presence or absence of ISO treatment, normalized to the number of pyknotic nuclei in cells infected with an empty virus expressing only a green fluorescent protein (GFP), in the absence of ISO treatment.

Statistical analysis

Data are presented as mean ± SEM. Statistical significance was determined with ANOVA, followed by Duncan multiple range comparison test using Super ANOVA (Abacus Concepts Inc). Differences were considered statistically significant at a value of $P < 0.05$.

Results

The active inhibitor-1 attenuates cardiac apoptosis induced by chronic isoproterenol treatment

The truncated, active I-1c has been shown to prevent cardiac cell apoptosis under ischemia/reperfusion conditions [24]. To examine whether this form of inhibitor-1 affects apoptosis induced by chronic β-agonist treatment in vivo, we treated mice expressing I-1c and their wild-type littermates with ISO by mini-pump infusion over a period of 14 days (50 μg/g per day). The TUNEL-staining assay revealed a lower proportion of TUNEL-positive nuclei in the myocardium of TG mice after ISO treatment, compared to WT (Fig. 1a, b). With an ELISA-based method measuring DNA fragmentation, we further confirmed that compared with saline treatment, chronic ISO treatment induced a dramatic increase in apoptosis by 69% in WT mice compared with TG mice where apoptosis increased by only 25%. In saline control groups, there were no differences in cellular apoptosis between WT and TG hearts (Fig. 1b, c).

To further confirm this finding in a system that lacks compensatory mechanisms which may occur in the transgenic hearts, we infected isolated rat adult cardiomyocytes with an adenovirus carrying the I-1c gene linked to a green fluorescent protein (GFP) gene that serves as an expression marker. As control, we used cardiomyocytes infected with an adenovirus expressing GFP only. Twenty-four hours following infection, the cells were incubated with 10 μmol/L ISO for an additional 24 h. We then evaluated the nuclear condensation in cardiomyocytes as an index of apoptosis, using the vital dye Hoechst 33342 (Fig. 2a). Consistent with previous reports [10, 13], chronic ISO treatment increased apoptosis, demonstrated by a 2.1-fold increase in the number of pyknotic nuclei in control or GFP infected cells (Fig. 2b). Although ISO treatment also increased apoptosis in I-1c infected cells, this effect was attenuated compared to control. Overall, these data indicate that I-1c protects against cellular apoptosis induced by chronic β-adrenergic stimulation.

The active inhibitor-1 attenuates the expression levels of pro-apoptotic proteins

To elucidate the mechanisms underlying the anti-apoptotic effect of I-1c, we assessed the expression levels of key players involved in either the intrinsic or the extrinsic apoptotic cascades. Chronic ISO treatment of WT animals decreased the expression levels of the anti-apoptotic protein Bcl-2, while it increased the pro-apoptotic protein Bax (Fig. 3a, b). However, these changes were diminished in the I-1c hearts. Interestingly, the ratio of Bcl-2 to Bax was

Fig. 1 Active inhibitor-1 (I-1c) expression protects hearts from apoptosis induced by chronic isoproterenol treatment. **a** Triple-staining with anti-α-sarcomeric actin antibody, DAPI, and TUNEL to determine apoptosis in ISO-treated wild type or active inhibitor-1 cardiomyocytes (*arrows* indicate TUNEL-positive nuclei); **b** counts of TUNEL-positive nuclei ($n = 5$); **c** DNA fragmentation assay measured with a cell death detection ELISA kit in ISO-treated WT and I-1 hearts ($n \geq 3$); *$P < 0.05$ compared with ISO-treated WT hearts; #$P < 0.05$ compared with saline treated hearts

twofold higher in TG (0.76 ± 0.12) than in WT mice hearts (0.38 ± 0.02; Fig. 3b). Surprisingly, in the absence of ISO treatment, TG mice exhibited a higher Bcl-2/Bax ratio (by 43%) compared with WT mice although this did not lead to any differences in apoptosis, as assessed in Figs. 1 and 3. We further determined the levels of caspase 8, commonly recognized as an extrinsic pro-apoptotic molecule. In saline-treated groups, the expression levels of cleaved caspase 8 were similar between WT and TG animals. ISO treatment, however, resulted in an increase (by 43%) in the protein levels of cleaved caspase 8 in WT animals, while this increase was attenuated in TG mice (Fig. 3a, c). A similar pattern of alteration was also observed for cleaved caspase 3, an active element involved in both extrinsic and intrinsic apoptotic pathways [32] (Fig. 3a, d). Altogether, these observations suggest that I-1c may maintain a high Bcl-2/Bax ratio that would prevent the release of mitochondrial apoptotic signals and preserve cell survival under chronic ISO treatment.

The active inhibitor-1 attenuates apoptosis by modulating the phosphorylation state of the pro-apoptotic protein Bad

Given that phosphorylated Bad, one of the Bcl-2 family members, has been reported to be a target of PP1 [1] and

that dephosphorylated Bad has a pro-apoptotic character [3], we tested the phosphorylation levels of Bad at three sites, ser112, ser136 and ser155. Interestingly, chronic ISO treatment caused varied alterations in the different phospho-sites of Bad. It elicited an increase in phosphorylation at ser112 by 2.48-fold, a decrease at ser136 by 63% and no changes at ser155 (Fig. 4b–d). Also, phosphorylation levels at the ser112 and ser155 sites were dramatically increased in the active inhibitor-1 animals at the basal state (2.7- and 2.6-fold, respectively). Importantly, the phosphorylation level at ser155 in the transgenic mice remained higher than WT under chronic ISO treatment (by 59%, Fig. 4d).

The active I-1c affects phosphorylation levels of ERK

Given the significant role of MAP kinase pathways in cardiac apoptosis [2, 5], we tested the phosphorylation levels of p38, ERK and JNK (Fig. 5a). The level of phosphorylated p38 was increased similarly in WT and active inhibitor-1 animals following ISO treatment (Fig. 5b). The ERK phosphorylation level was decreased by 55% with ISO treatment in WT mice. However, under ISO treatment, the level of ERK phosphorylation was higher (by 53%, Fig. 5c) in TG compared with WT mice. The levels of phosphorylated JNK (Fig. 5d) or Akt (data not shown) were not altered by either chronic ISO

Fig. 2 Active I-1c expression protects adult rat cardiomyocytes from apoptosis induced by prolonged isoproterenol treatment. **a** Adenoviral-infected cells were stained with Hoechst 33342 after exposure to ISO for 24 h and fluorescence was examined (magnification ×300); **b** basal and ISO-induced pyknotic nuclei under Hoechst staining were counted and expressed as the percentage of total nuclei ($n = 3$); $*P < 0.05$ compared with ISO-treated WT hearts; $\#P < 0.05$ compared with saline-treated hearts


treatment or expression of inhibitor-1. These data indicate that in I-1c mice under chronic stress, the ERK signaling pathway appears to be activated. Altogether the data suggest that attenuation of apoptosis observed experimentally in I-1c mice under chronic stress, might be mediated not only through the activation of the mitochondrial-related pro-survival mechanisms mentioned above, but also through activation of the ERK survival signaling cascade.

Discussion

Recently, cell death/apoptosis has been recognized as an important player in heart failure development and especially the transition from compensated to failing status. A key characteristic of human and experimental heart failure

is elevated activity of PP1. Importantly, inhibition of PP1 by a truncated and constitutively active (T35D) inhibitor-1 enhanced basal cardiac function, attenuated heart failure induced by chronic overload and protected against ischemic injury [7, 26]. In this study, we report that this active form of inhibitor-1 may also attenuate apoptosis induced by chronic β-adrenergic stimulation in the heart. Prolonged activation of the sympathetic nervous system and constantly elevated catecholamine levels contribute to the progression of heart failure [19]. Apoptosis induced by chronic β-adrenergic stimulation may be one of the underlying mechanisms in this process [10, 29]. Furthermore, reduced levels of inhibitor-1 and elevated activity of PP1 have been observed following long-term β-adrenergic stimulation [4, 11]. In this study, we observed that expression of the active inhibitor-1 attenuated cardiac

Fig. 3 Active I-1c expression diminishes the changes in the protein levels of apoptosis-regulatory molecules induced by chronic isoproterenol treatment. **a** Representative blots; **b** ratio of Bcl-2/Bax. **c** cleaved caspase 8; **d** cleaved caspase 3. $n \geq 3$, *$P < 0.05$ compared with ISO-treated WT hearts; #$P < 0.05$ compared with saline-treated hearts


apoptosis associated with prolonged β-stimulation. The underlying mechanisms may involve altered expression and phosphorylation levels of proteins that belong to the Bcl-2 family and/or MAP kinase pathways. Indeed, the MAP kinase pathways have been shown to play an important role in cardiac apoptosis [2]. Furthermore, accumulating evidence indicates that various protein kinases [2, 18] and phosphatases [33] may regulate apoptosis by targeting cytosolic and/or mitochondrial proteins. Specifically, phosphorylation of ERK or JAK was shown to induce cardioprotection [2, 15], whereas phosphorylation of JNK or p38 had a predominantly pro-apoptotic effect [2, 18]. Thus, the observed increases in phosphorylation of ERK, which has been reported to be under regulation by PP1 through MEK [36], may contribute to the protective effects under prolonged ISO stimulation of transgenic hearts.

Interestingly, we observed for the first time that chronic ISO exposure caused opposed changes in the phosphorylation levels of different sites in Bad. In its phosphorylated form, Bad promotes cell survival whereas in its dephosphorylated form, Bad associates with Bcl-X_L at the mitochondrial membrane, preventing its anti-apoptotic activity

and promoting cell death. It has been reported that Bad phosphorylation at ser155 triggers the dissociation of Bad from Bcl-X_L [21, 31], which in turn leads to cell survival. Although the available data suggest that PP1 is involved in Bad dephosphorylation at ser112 and ser136 [21, 22], there is no evidence suggesting that PP1 is also involved in the dephosphorylation of ser155. Our data indicate that phosphorylation of ser155 was increased under basal conditions in I-1c hearts and higher phosphorylation levels were also observed upon chronic exposure to ISO (Fig. 4d). This may partially contribute to the cardioprotective effects mediated by the active inhibitor-1. However, a limitation of this study is that there was no evidence presented that the findings associated with chronic ISO stimulation could be prevented by pre-incubation with a beta-blocker.

In addition to the possibility of directly regulating the phosphorylation levels of the signaling proteins, the active inhibitor-1 may elicit its effects on signaling transduction by other mechanisms including Ca^{2+}-dependent cascades. It is well known that the active inhibitor-1 can regulate the sarcoplasmic reticulum function and thus Ca^{2+}-homeostasis, mainly by affecting the phosphorylation level of phospholamban [7, 26]. Indeed, accumulating evidence

Fig. 4 Active I-1c expression alters the phosphorylation levels of Bad. **a** Representative blots; **b** ratio of phosphorylated ser112/total Bad; **c** ratio of phosphorylated ser136/total Bad; **d** ratio of phosphorylated ser155/total Bad. $n \geq 3$; $*P < 0.05$ compared with ISO-treated WT hearts; $^{\#}P < 0.05$ compared with saline-treated hearts


suggests that the SR may be involved in the apoptotic processes by interacting with the mitochondria [9, 17]. In particular, phospholamban has been implicated in myocardial cell apoptosis through a Ca^{2+}-dependent pathway [34, 35]. Based on the critical role of inhibitor-1 in regulating the phosphorylation level of phospholamban and SR function, it is interesting to propose that at least part of the beneficial effects of this molecule may be attributed to its effects on improved Ca^{2+} homeostasis. Interestingly, these I-1 beneficial effects may appear contradictory to recent findings in an I-1 knockout and an I-1c inducible mouse model. It was reported that under conditions of increased adrenergic drive, the I-1 deficient mouse shows cardioprotection [12], while the inducible I-1c model, generated on an I-1 deficient background, exhibits a decline in fractional shortening accompanied by an increase in left ventricular dilation, hypertrophy and increased interstitial fibrosis [37]. However, we did not observe cardiac deterioration following β-adrenergic stress. Actually, not only was apoptosis halted by I-1c overexpression but contractility remained enhanced in I-1c hearts (assessed by catheterization) (+dP/dt, 7,052 ± 489 and 9,216 ± 375; −dP/dt, 7,075 ± 421 and 8,902 ± 555 in WT and TG mice, respectively). Furthermore, the end-diastolic pressure

(EDP) was much lower (4.0 ± 0.5) in I-1c than WT hearts (7.1 ± 1.4). This apparent discrepancy between our findings and those reported earlier [12, 37] may be due to differences in the mouse genetic background (FVB/N vs. C57Bl/6J), overexpression of I-1c in the presence (present study) or absence [37] of endogenous I-1 and environmental factors in mouse husbandry.

As indicated above, changes in Ca^{2+}-cycling play a vital role in cellular apoptosis [27]. The active inhibitor-1 may prevent cell death by its ability to improve the Ca^{2+} balance in cells under stress. Interestingly, based on the universal effects of Ca^{2+} on multiple cellular pathways [27], this mechanism may allow this form of inhibitor-1 to offer cell protection under different pathways. For example, endoplasmic reticulum (ER) stress is a proposed detrimental mechanism for acute ischemia/reperfusion-induced cell injury [30]. Our recent data showed that apoptosis induced by ischemia/reperfusion was decreased by inducible expression of active inhibitor-1 through attenuated ER stress [24]. Meanwhile, as revealed in this study, increased phosphorylation of signaling proteins such as Bad and ERK may be the major mechanisms for the protective effects in the transgenic hearts, responding to prolonged β-adrenergic activation. Thus, the active inhibitor-1 may prevent cell

Fig. 5 Active I-1c expression diminishes the changes in the levels of phosphorylated ERK induced by chronic isoproterenol treatment. **a** Representative blots; **b** ratio of phosphorylated/total p38; **c** ratio of phosphorylated/total ERK; **d** ratio of phosphorylated/total JNK. $n \geq 3$; $*P < 0.05$ compared with ISO-treated WT hearts; $^{\#}P < 0.05$ compared with saline-treated hearts

death through pathways associated with improved Ca^{2+} homeostasis and phosphorylation of key signaling players in the heart.

References

1. Ayllón V, Martínez AC, García A, Cayla X, Rebollo A (2000) Protein phosphatase 1alpha is a Ras-activated Bad phosphatase that regulates interleukin-2 deprivation-induced apoptosis. EMBO J 19:2237–2246

2. Baines CP, Molkentin JD (2005) STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 38:47–62

3. Bergmann A (2002) Survival signaling goes BAD. Dev Cell 3:607–608

4. Boknik P, Fockenbrock M, Herzig S, Knapp J, Linck B, Lüss H, Müller FU, Müller T, Schmitz W, Schröder F, Neumann J (2000) Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation. Naunyn Schmiedeberg's Arch Pharmacol 362:222–231

5. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286:1358–1362

6. Bowles NE, Towbin JA (1998) Molecular aspects of myocarditis. Curr Opin Cardiol 13:179–184

7. Carr AN, Schmidt AG, Suzuki Y, del Monte F, Sato Y, Lanner C, Breeden K, Jing SL, Allen PB, Greengard P, Yatani A, Hoit BD, Grupp IL, Hajjar RJ, DePaoli-Roach AA, Kranias EG (2002) Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 22:4124–4135

8. Chen G, Zhou X, Nicolaou P, Rodriguez P, Song G, Mitton B, Pathak A, Zachariah A, Fan GC, Dorn GW, Kranias EG (2008) A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to beta-adrenergic stimulation. FASEB J 22:1790–1796

9. Chen X, Zhang X, Kubo H, Harris DM, Mills GD, Moyer J, Berretta R, Potts ST, Marsh JD, Houser SR (2005) Ca2+ influx-induced sarcoplasmic reticulum Ca2+ overload causes mitochondrial-dependent apoptosis in ventricular myocytes. Circ Res 97:1009–1017

10. Communal C, Singh K, Pimentel DR, Colucci WS (1998) Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 98:1329–1334

11. El-Armouche A, Gocht F, Jaeckel E, Wittköpper K, Peeck M, Eschenhagen T (2007) Long-term beta-adrenergic stimulation leads to downregulation of protein phosphatase inhibitor-1 in the heart. Eur J Heart Fail 9:1077–1080

12. El-Armouche A, Wittköpper K, Degenhardt F, Weinberger F, Didié M, Melnychenko I, Grimm M, Peeck M, Zimmermann WH, Unsöld B, Hasenfuss G, Dobrev D, Eschenhagen T (2008) Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc Res 80:396–406

13. Fan GC, Chu G, Mitton B, Song Q, Yuan Q, Kranias EG (2004) Small heat-shock protein Hsp20 phosphorylation inhibits beta-agonist-induced cardiac apoptosis. Circ Res 94:1474–1482

14. Fan GC, Yuan Q, Song G, Wang Y, Chen G, Qian J, Zhou X, Lee YJ, Ashraf M, Kranias EG (2006) Small heat-shock protein Hsp20 attenuates beta-agonist-mediated cardiac remodeling through apoptosis signal-regulating kinase 1. Circ Res 99:1233–1242

15. Fuglesteg BN, Suleman N, Tiron C, Kanhema T, Lacerda L, Andreasen TV, Sack MN, Jonassen AK, Mjøs OD, Opie LH, Lecour S (2008) Signal transducer and activator of transcription 3 is involved in the cardioprotective signaling pathway activated by insulin therapy at reperfusion. Bas Res Cardiol 103:444–453

16. Garcia A, Cayla X, Guergnon J, Dessauge F, Hospital V, Rebollo MP, Fleischer A, Rebollo A (2003) Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie 85:721–726

17. George CH, Rogers SA, Bertrand BM, Tunwell RE, Thomas NL, Steele DS, Cox EV, Pepper C, Hazeel CJ, Claycomb WC, Lai FA (2007) Alternative splicing of ryanodine receptors modulates cardiomyocyte Ca2+ signaling and susceptibility to apoptosis. Circ Res 100:874–883

18. Heusch G, Boengler K, Schulz R (2008) Cardioprotection—nitric oxide, protein kinases and mitochondria. Circulation 118:1915–1919

19. Kaye D, Esler M (2005) Sympathetic neuronal regulation of the heart in aging and heart failure. Cardiovasc Res 66:256–264

20. Khoynezhad A (2007) Promising aspects and caveats of studies on anti-apoptotic therapies in patients with heart failure. Eur J Heart Fail 9:120–123

21. Klumpp S, Krieglstein J (2002) Serine/threonine protein phosphatases in apoptosis. Curr Opin Pharmacol 2:458–462

22. Krijnen PA, Nijmeijer R, Meijer CJLM, Visser CA, Hack CE, Niessen HWM (2002) Apoptosis in myocardial ischaemia and infarction. J Clin Pathol 55:801–811

23. Lips DJ, Nagel TVD, Steendijk P, Palmen M, Janssen BJ, Dantzig JV, Windt LJD, Doevendans PA (2004) Left ventricular pressure–volume measurements in mice: comparison of close chest versus open-chest approach. Basic Res Cardiol 99:351–359

24. Nicolaou P, Rodriguez P, Ren X, Zhou X, Qian J, Sadayappan S, Mitton B, Pathak A, Robbins J, Hajjar RJ, Jones K, Kranias EG (2009) Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res 104:1012–1020

25. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P (1997) Apoptosis in the failing human heart. N Engl J Med 336:1131–1141

26. Pathak A, del Monte F, Zhao W, Schultz JE, Lorenz JN, Bodi I, Weiser D, Hahn H, Carr AN, Syed F, Mavila N, Jha L, Qian J, Marreez Y, Chen G, McGraw DW, Heist EK, Guerrero JL, DePaoli-Roach AA, Hajjar RJ, Kranias EG (2005) Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 96:756–766

27. Pinton P, Giorgi C, Siviero R, Zecchini E, Rizzuto R (2008) Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene 27:6407–6418

28. Rodriguez P, Mitton B, Nicolaou P, Chen G, Kranias EG (2007) Phosphorylation of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes. Am J Physiol Heart Circ Physiol 293:H762–H769

29. Singh K, Communal C, Sawyer DB, Colucci WS (2000) Adrenergic regulation of myocardial apoptosis. Cardiovasc Res 45:713–719

30. Szegezdi E, Duffy A, O'Mahoney ME, Logue SE, Mylotte LA, O'Brien T, Samali A (2006) ER stress contributes to ischemia-induced cardiomyocyte apoptosis. Biochem Biophys Res Commun 349:1406–1411

31. Tan Y, Demeter MR, Ruan H, Comb MJ (2000) BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem 275:25865–25869

32. Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science 281:1312–1316

33. Totzeck A, Boengler K, Van den Sand A, Konietzka I, Gres P, Garcia-Dorado D, Heusch G, Schultz R (2008) No impact of protein phosphatases on connexin 43 phosphorylation in ischemic preconditioning. Am J Physiol Heart Circ Physiol 295:H2106–H2112

34. Vafiadaki E, Arvanitis DA, Pagakis SN, Papalouka V, Sanoudou D, Kontrogianni-Konstantopoulos A, Kranias EG (2009) The anti-apoptotic protein HAX-1 interacts with SERCA2 and regulates its protein levels to promote cell survival. Mol Biol Cell 20:306–318

35. Vafiadaki E, Sanoudou D, Arvanitis DA, Catino DH, Kranias EG, Kontrogianni-Konstantopoulos A (2007) Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function. J Mol Biol 367:65–79

36. Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, Corvol JC, Stipanovich A, Caboche J, Lombroso PJ, Nairn AC, Greengard P, Herve D, Girault JA (2005) Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci USA 102:491–496

37. Wittköpper K, Fabritz L, Neef S, Ort KR, Grefe C, Unsöld B, Kirchhof P, Maier LS, Hasenfuss G, Dobrev D, Eschenhagen T, El-Armouche A (2010) Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest 120:617–626

38. Zhao W, Fan GC, Zhang ZG, Bandyopadhyay A, Zhou X, Kranias EG (2009) Protection of peroxiredoxin II on oxidative stress-induced cardiomyocyte death and apoptosis. Bas Res Cardiol 104:377–389